Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

R. A. Fromtling, John N Galgiani, M. A. Pfaller, A. Espinel-Ingroff, K. F. Bartizal, M. S. Bartlett, B. A. Body, C. Frey, G. Hall, G. D. Roberts, F. B. Nolte, F. C. Odds, M. G. Rinaldi, A. M. Sugar, K. Villareal

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 104 and 2.5 x 103 cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC- 2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume37
Issue number1
StatePublished - 1993
Externally publishedYes

Fingerprint

Yeasts
Candida glabrata
Flucytosine
Reading
Ketoconazole
Amphotericin B
Candida
Candida tropicalis
Cryptococcus neoformans
Candida albicans
Pharmaceutical Preparations
Multicenter Studies
Growth

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Fromtling, R. A., Galgiani, J. N., Pfaller, M. A., Espinel-Ingroff, A., Bartizal, K. F., Bartlett, M. S., ... Villareal, K. (1993). Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrobial Agents and Chemotherapy, 37(1), 39-45.

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. / Fromtling, R. A.; Galgiani, John N; Pfaller, M. A.; Espinel-Ingroff, A.; Bartizal, K. F.; Bartlett, M. S.; Body, B. A.; Frey, C.; Hall, G.; Roberts, G. D.; Nolte, F. B.; Odds, F. C.; Rinaldi, M. G.; Sugar, A. M.; Villareal, K.

In: Antimicrobial Agents and Chemotherapy, Vol. 37, No. 1, 1993, p. 39-45.

Research output: Contribution to journalArticle

Fromtling, RA, Galgiani, JN, Pfaller, MA, Espinel-Ingroff, A, Bartizal, KF, Bartlett, MS, Body, BA, Frey, C, Hall, G, Roberts, GD, Nolte, FB, Odds, FC, Rinaldi, MG, Sugar, AM & Villareal, K 1993, 'Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts', Antimicrobial Agents and Chemotherapy, vol. 37, no. 1, pp. 39-45.
Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrobial Agents and Chemotherapy. 1993;37(1):39-45.
Fromtling, R. A. ; Galgiani, John N ; Pfaller, M. A. ; Espinel-Ingroff, A. ; Bartizal, K. F. ; Bartlett, M. S. ; Body, B. A. ; Frey, C. ; Hall, G. ; Roberts, G. D. ; Nolte, F. B. ; Odds, F. C. ; Rinaldi, M. G. ; Sugar, A. M. ; Villareal, K. / Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. In: Antimicrobial Agents and Chemotherapy. 1993 ; Vol. 37, No. 1. pp. 39-45.
@article{475f55d243c646b8b9048f8486c9ad1a,
title = "Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts",
abstract = "Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 104 and 2.5 x 103 cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87{\%} for different inocula, times of incubation, and end point criteria. Agreement was maximized (85{\%}) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC- 2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.",
author = "Fromtling, {R. A.} and Galgiani, {John N} and Pfaller, {M. A.} and A. Espinel-Ingroff and Bartizal, {K. F.} and Bartlett, {M. S.} and Body, {B. A.} and C. Frey and G. Hall and Roberts, {G. D.} and Nolte, {F. B.} and Odds, {F. C.} and Rinaldi, {M. G.} and Sugar, {A. M.} and K. Villareal",
year = "1993",
language = "English (US)",
volume = "37",
pages = "39--45",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

AU - Fromtling, R. A.

AU - Galgiani, John N

AU - Pfaller, M. A.

AU - Espinel-Ingroff, A.

AU - Bartizal, K. F.

AU - Bartlett, M. S.

AU - Body, B. A.

AU - Frey, C.

AU - Hall, G.

AU - Roberts, G. D.

AU - Nolte, F. B.

AU - Odds, F. C.

AU - Rinaldi, M. G.

AU - Sugar, A. M.

AU - Villareal, K.

PY - 1993

Y1 - 1993

N2 - Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 104 and 2.5 x 103 cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC- 2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.

AB - Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 104 and 2.5 x 103 cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC- 2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.

UR - http://www.scopus.com/inward/record.url?scp=0027448391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027448391&partnerID=8YFLogxK

M3 - Article

C2 - 8431016

AN - SCOPUS:0027448391

VL - 37

SP - 39

EP - 45

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -